OraSure Technologies, Inc.
OraSure Technologies provides diagnostic tests and products for point-of-care and home use. Products include COVID-19 rapid tests, HIV/HCV tests, drug testing systems, and genomic collection devices. The company also offers microbiome laboratory and analytical services. Additional products include immunoassays, in vitro diagnostic tests, and saliva alcohol test kits. OraSure markets its products to various industries, including clinical laboratories, hospitals, and government agencies. The company was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Overview
Sector
Medical Instruments & Supplies
Strengths
- Price to book ratio (0.50) is lower than the sector mean (3.86).
- EV/EBITDA (5.08) is lower than the sector mean (47.53).
- EV/EBIT (1.95) is lower than the sector mean.
- Price to free cash flow (8.76) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (27.64) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (6.44%) is significantly lower than the sector mean (8.23%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 4.8 |
| Price/Free Cash Flow' | 8.9 |
| ROIC | 6.4% |
| Net Debt/EBITDA | 27.6 |